Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bebtelovimab - Eli Lilly and Company

X
Drug Profile

Bebtelovimab - Eli Lilly and Company

Alternative Names: ABCL-1404; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404; LY-CoV1404 monoclonal antibody

Latest Information Update: 20 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Abcellera; Eli Lilly and Company
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration COVID 2019 infections

Most Recent Events

  • 16 Feb 2023 US FDA unauthorises the use of Bebtelovimab for COVID-2019 infections (In adolescents, In adults, In children, Mild to moderate-stage disease) in USA
  • 30 Nov 2022 US FDA unauthorises the use of bebtelovimab under emergency use authorization for COVID-2019 infections (Early-stage disease, In adolescents, In adults, In children, Mid-stage disease, Monotherapy) in USA
  • 04 Aug 2022 Eli Lilly intends to make Bebtelovimab commercially available for purchase by U.S. states/territories, hospitals, and a broad set of other providers through a sole distributor.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top